CLDN3 and ovarian carcinoma: Additional evidence supporting the suppressive role of CD151-α3β1 integrin complexes in ovarian cancer comes from the loss of tumor-promoting molecules within CD151-deficient TEMM, such as CD9 and claudin-3 (Fig. 4).